OncoSec Medical Inc. said FDA has granted the orphan drug designation for pIL-12, otherwise known as tavokinogene telsaplasmid, for the treatment of unresectable metastatic melanoma. Tavokinogene telsaplasmid is the active biologic agent in OncoSec’s lead product candidate, ImmunoPulse IL-12.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
